A detailed history of Marshall Wace, LLP transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 43,500 shares of KROS stock, worth $731,235. This represents 0.0% of its overall portfolio holdings.

Number of Shares
43,500
Previous 22,377 94.4%
Holding current value
$731,235
Previous $1.02 Million 147.16%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$41.68 - $58.07 $880,406 - $1.23 Million
21,123 Added 94.4%
43,500 $2.53 Million
Q2 2024

Aug 14, 2024

SELL
$44.58 - $66.89 $11.2 Million - $16.8 Million
-250,594 Reduced 91.8%
22,377 $1.02 Million
Q1 2024

May 15, 2024

BUY
$41.26 - $70.48 $9.22 Million - $15.8 Million
223,499 Added 451.77%
272,971 $18.1 Million
Q4 2023

Feb 14, 2024

BUY
$27.12 - $41.05 $1.34 Million - $2.03 Million
49,472 New
49,472 $1.97 Million
Q2 2023

Aug 14, 2023

SELL
$37.26 - $51.01 $2.01 Million - $2.75 Million
-53,870 Reduced 46.23%
62,650 $2.52 Million
Q1 2023

May 15, 2023

BUY
$41.44 - $59.32 $4.56 Million - $6.53 Million
110,120 Added 1720.63%
116,520 $4.98 Million
Q4 2022

Feb 14, 2023

BUY
$39.45 - $51.77 $252,480 - $331,328
6,400 New
6,400 $307,000
Q2 2022

Aug 15, 2022

BUY
$26.03 - $67.04 $1.18 Million - $3.05 Million
45,466 Added 608.81%
52,934 $1.46 Million
Q1 2022

May 16, 2022

BUY
$42.12 - $59.36 $73,330 - $103,345
1,741 Added 30.4%
7,468 $406,000
Q4 2021

Feb 14, 2022

SELL
$36.95 - $62.89 $1.62 Million - $2.76 Million
-43,909 Reduced 88.46%
5,727 $335,000
Q3 2021

Nov 15, 2021

BUY
$29.27 - $43.71 $1.1 Million - $1.64 Million
37,581 Added 311.75%
49,636 $1.96 Million
Q2 2021

Aug 13, 2021

BUY
$42.4 - $70.11 $261,947 - $433,139
6,178 Added 105.12%
12,055 $512,000
Q1 2021

May 17, 2021

SELL
$54.0 - $75.28 $627,210 - $874,377
-11,615 Reduced 66.4%
5,877 $362,000
Q4 2020

Feb 16, 2021

BUY
$36.0 - $82.74 $629,712 - $1.45 Million
17,492 New
17,492 $1.23 Million

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $433M
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.